Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Pharmacol ; 65(3): 558-70, 2004 Mar.
Article in English | MEDLINE | ID: mdl-14978234

ABSTRACT

Concentrative nucleoside transporters (CNTs) and equilibrative nucleoside transporters (ENTs) are important in physiological and pharmacological activity and disposition of nucleosides and nucleoside drugs. A better understanding of the structural requirements of inhibitors for these transporters will aid in designing therapeutic agents. To define the relative and unified structural requirements of nucleoside analogs for interaction with hCNT1, hCNT2, and hENT1, we applied an array of structure-activity techniques. Unique pharmacophore models for each respective nucleoside transporter were generated. These models reveal that hCNT2 affinity is dominated by hydrogen bonding features, whereas hCNT1 and hENT1 displayed mainly electrostatic and steric features. Hydrogen bond formation over 3'-OH is essential for all nucleoside transporters. Inhibition of nucleoside transporters by a series of uridine and adenosine analogs and a variety of drugs was analyzed by comparative molecular field analysis. Cross-validated r2 (q2) values were 0.65, 0.52, and 0.74 for hCNT1, hCNT2, and hENT1, respectively. The predictive quality of the models was further validated by successful prediction of the inhibition of a set of test compounds. Addition of a hydroxyl group around the 2-position of purine (or 3-position of pyrimidine) may increase inhibition to hCNT2 transporter; addition of hydroxyl group around the 2,7-position of purine (or the 3,5-position of pyrimidine) would increase the inhibition to hENT1 transporter. Utilization of these models should assist the design of high-affinity nucleoside transporter inhibitors and substrates for both anticancer and antiviral therapy.


Subject(s)
Equilibrative Nucleoside Transporter 1/metabolism , Membrane Transport Proteins/metabolism , Nucleosides/metabolism , Biological Transport , Equilibrative Nucleoside Transporter 1/chemistry , Humans , Membrane Transport Proteins/chemistry , Models, Molecular , Nucleoside Transport Proteins/metabolism , Nucleosides/chemistry , Structure-Activity Relationship
2.
Am J Physiol Gastrointest Liver Physiol ; 280(3): G475-81, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11171631

ABSTRACT

The objectives of our study were to identify the types of nucleoside transporters present in the human fetal small intestine and to characterize their developmental activity, longitudinal distribution, and transport kinetics compared with those present in the adult intestine. Nucleoside uptake by intestinal brush-border membrane vesicles was measured by an inhibitor-stop rapid filtration technique. Only the purine-specific (N1; hCNT2) and the pyrimidine-specific (N2; hCNT1) Na(+)-dependent nucleoside transporters were found to be present on the brush-border membranes of the enterocytes along the entire length of the fetal and adult small intestines. The activity of these transporters was higher in the proximal than in the distal small intestine. Both the N1 and N2 transporters found in the fetal intestine shared similar kinetic properties (Michaelis-Menten constant and Na(+)-nucleoside stoichiometry) to those in the adult intestine. During the period of rapid morphogenesis (11-15 wk gestation), no temporal differences were apparent in the activity of the N1 and N2 transporters in the fetal small intestine. These findings have implications for the absorption of drugs from the amniotic fluid by the fetus after maternal drug administration of nucleoside drugs such as the antivirals zidovudine and didanosine.


Subject(s)
Carrier Proteins/metabolism , Intestine, Small/metabolism , Membrane Transport Proteins , Thioinosine/analogs & derivatives , Adult , Biological Transport , Carrier Proteins/genetics , Cell Membrane/chemistry , Cell Membrane/metabolism , Cytidine/pharmacokinetics , Cytoplasmic Vesicles/chemistry , Cytoplasmic Vesicles/metabolism , Drug Design , Female , Fetus , Gene Expression Regulation, Developmental , Guanosine/pharmacokinetics , Humans , Inosine/pharmacokinetics , Intestine, Small/chemistry , Male , Microvilli/metabolism , Organ Specificity , Protein Isoforms , Sodium/metabolism , Thioinosine/pharmacokinetics , Uridine/pharmacokinetics
3.
Cancer Chemother Pharmacol ; 46(5): 394-402, 2000.
Article in English | MEDLINE | ID: mdl-11127944

ABSTRACT

PURPOSE: To determine the structure-inhibitory profiles of nucleosides for the N1 and N2 Na+-nucleoside transporters of the human intestine. METHODS: The uptake of 3H-labeled prototypic substrates of the N1 (inosine) and N2 (thymidine) transporters into human intestinal brush border membrane vesicles was measured by a rapid filtration technique in the presence and absence of various uridine and adenosine analogs and antiviral and anticancer nucleoside drugs (100 and 1000 microM). RESULTS: In the ribose ring, the 3'-oxygen is required for inhibition of uptake of nucleosides by both the N1 and N2 transporters. The structural requirements for such inhibition differ with respect to modifications on the 5' position of the sugar ring or on the base. The N2 transporter is more tolerant to these substitutions than is the N1 transporter. The 6 position on uracil and the 8 position on adenine are critical for inhibition of uptake of nucleosides by both the N1 and N2 nucleoside transporters. CONCLUSIONS: These data are the first evidence that the binding site(s) of the human N1 and N2 transporters differ in their interaction with analogs of their common substrates, uridine and adenosine. Such studies can provide insight into the critical structural determinants of the substrate necessary for recognition by the Na+-nucleoside transporters of the human intestine.


Subject(s)
Carrier Proteins/antagonists & inhibitors , Intestinal Mucosa/metabolism , Membrane Transport Proteins , Nucleosides/pharmacology , Adenosine/analogs & derivatives , Adenosine/pharmacology , Humans , In Vitro Techniques , Inosine/analogs & derivatives , Inosine/pharmacology , Intestines/drug effects , Microvilli/drug effects , Microvilli/metabolism , Structure-Activity Relationship , Thymidine/analogs & derivatives , Thymidine/pharmacology , Uridine/analogs & derivatives , Uridine/pharmacology
4.
Cancer Chemother Pharmacol ; 45(4): 273-8, 2000.
Article in English | MEDLINE | ID: mdl-10755314

ABSTRACT

PURPOSE: To clone and sequence the equilibrative nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporter (es) from the human small intestine and to examine the capacities of nucleosides and nucleoside analogs to inhibit the uptake of uridine by this transporter. METHODS: Using PCR, es was cloned from a cDNA library of the human small intestine. The uptake of 3H-uridine (10 microM) by the recombinant es, expressed in Xenopus oocytes, was measured in the presence (2 mM) and absence of nucleosides and nucleoside analogs. RESULTS: The amino acid sequence of this es transporter was identical to that of the human placental es transporter. Uptake of 3H-uridine by this es transporter was inhibitable by 1 microM NBMPR. Removal of the oxygen from the 3' position or from both the 2' and 3' positions, but not from 2' or 5' position, resulted in a partial or total loss of the capacity of the nucleosides to inhibit 3H-uridine uptake. No modifications of the adenosine base or of the uridine base (except for 3 and 6 positions on uracil) affected nucleoside inhibitory capacity. CONCLUSION: The es transporters of the human intestine and placenta are identical in their amino acid sequences. Moreover, the inhibitory profiles of various nucleoside analogs in inhibiting the uptake of uridine by the intestinal es transporter are similar to those obtained with the as-yet-uncloned human erythrocyte es transporter. Collectively, these findings suggest that the es transporter does not appear to be functionally variant in the human placenta, small intestine or erythrocytes.


Subject(s)
Carrier Proteins/genetics , Intestine, Small/metabolism , Membrane Proteins/genetics , Nucleosides/antagonists & inhibitors , Animals , Carrier Proteins/chemistry , Gene Library , Humans , Membrane Proteins/chemistry , Nucleoside Transport Proteins , Plasmids/genetics , Reverse Transcriptase Polymerase Chain Reaction , Thioinosine/analogs & derivatives , Thioinosine/pharmacology , Uridine/metabolism , Xenopus laevis
5.
Antimicrob Agents Chemother ; 43(6): 1516-9, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10348786

ABSTRACT

To evaluate if atovaquone (ATQ) interacts pharmacokinetically with azithromycin (AZ) in human immunodeficiency virus-infected children, 10 subjects (ages, 4 to 13 years) were randomized in a crossover study to receive AZ (5 mg/kg/day) alone (ALONE) or AZ (5 mg/kg/day) and ATQ (30 mg/kg/day) simultaneously (SIM) prior to receiving AZ and ATQ staggered by 12 h. Despite a lack of significant difference in the mean AZ pharmacokinetic parameters, the steady-state values of AZ's area under the concentration-time curve from 0 to 24 h and maximum concentration in serum were consistently lower (n = 7 of 7) for the SIM regimen than they were for the ALONE regimen. A larger study will be required to determine if ATQ affects AZ pharmacokinetics and efficacy in a clinically significant manner.


Subject(s)
Acquired Immunodeficiency Syndrome/metabolism , Anti-Bacterial Agents/pharmacokinetics , Antifungal Agents/pharmacology , Azithromycin/pharmacokinetics , HIV-1 , Naphthoquinones/pharmacology , Adolescent , Atovaquone , Azithromycin/administration & dosage , Child , Child, Preschool , Cross-Over Studies , Drug Interactions , Humans , Naphthoquinones/administration & dosage
7.
J Pharm Sci ; 86(8): 944-52, 1997 Aug.
Article in English | MEDLINE | ID: mdl-9269873

ABSTRACT

In this study, potential alterations in hepatic blood flow, plasma protein binding, hepatic tissue binding, and enzyme activities induced by LD iv infusion of lidocaine (LD) were evaluated using a chronically instrumented dog model. Four conscious female mongrel dogs (19.0-23.5 kg) were each given, on days 1 and 10, a 5-min infusion of a mixture of unlabeled LD at approximately 2 mg/kg and 14C-labeled LD at approximately 25 microCi and, on day 8, a 12-h constant rate iv infusion of LD (approximately 76 microg/kg/min). During LD infusion, there was a 11-79% increase in total hepatic blood flow, mainly due to a 1.6-9.2-fold increase in hepatic arterial flow. Despite similar blood clearance (27.5 +/- 6.0 mL/min/kg vs 27.5 +/- 3.5 mL/min/kg), volume of distribution at steady state (1.38 +/- 0.08 L/kg vs 1.36 +/- 0.17 L/kg), and free fraction values of LD between days 1 and 10 (p > 0.05), intrinsic clearance values were consistently reduced (1224 +/- 859 mL/ min/kg vs 285 +/- 104 mL/min/kg; p = 0.034). Furthermore, hepatic tissue uptake of LD and/or its metabolites was less on day 10 than on day 1 (39.7 +/- 14.5 micromol vs 30.1 +/- 15.1 micromol; p = 0.072). The extent of N-dealkylation of LD to MEGX was unaltered, whereas sequential biotransformation of MEGX was impaired. Hence, these findings suggested that LD infusion led to a reduction of hepatic intrinsic clearance, although the change was not significant enough to alter its conventional kinetic parameters.


Subject(s)
Lidocaine/administration & dosage , Animals , Area Under Curve , Dogs , Female , Infusions, Intravenous , Lidocaine/pharmacokinetics , Lidocaine/pharmacology , Liver/blood supply , Liver/metabolism , Regional Blood Flow/drug effects
9.
Ther Drug Monit ; 13(4): 304-8, 1991 Jul.
Article in English | MEDLINE | ID: mdl-1780961

ABSTRACT

To help clarify whether food or enteral nutrients decrease hydralazine relative bioavailability, eight subjects were given oral hydralazine under four nutritional conditions: fasted (F), with a standard breakfast (SB), with a bolus of enteral nutrients (EB), and with a slow infusion of enteral nutrients administered by nasogastric tube (EI). The area under the curve and maximum concentration values were much higher under the fasted and enteral infusion conditions than under the standard breakfast or enteral bolus conditions, indicating that the absorption and/or disposition kinetics of hydralazine may be altered by food. The median (range) values for these parameters were 2,641 (385-4,747) and 87 (4.5-224) for F; 1,189 (202-1,737) and 15 (3.5-33.9) for SB; 999 (227-3,576) and 11 (2.5-50) for EB; and 3,068 (313-4,917) ng/ml/min and 113 (3.6-235) ng/ml for EI. Furthermore, the rate of nutrient administration, but not necessarily the physical form, of the nutrients appears to be a significant factor in determining the magnitude of the food effect. The nutrient interaction should be accounted for in patients receiving hydralazine and enteral nutrition concomitantly.


Subject(s)
Enteral Nutrition , Food, Formulated , Hydralazine/pharmacokinetics , Administration, Oral , Adult , Biological Availability , Drug Interactions , Fasting , Female , Humans , Hydralazine/administration & dosage , Intubation, Gastrointestinal , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...